Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Cash Register: Part II" staring AntiMarketMaker, Starbuxsux with guest appearances by IHub traders who follow these guys to $$ land.
Ok, that's more like it.
Tomorrow, we will see a hard push down on the stock. Once 2015 hits, game on!
More than likely, the Algos are going to make one more final push. Then they will let up a little starting Friday, Jan 2nd.
Monday, January 5th? Game on, brother.
Too late to correct the image. Dinner has already ejected from my stomach. Thanks, JohnCM!
It's room for everyone in the market, not just investors.
The sound of the cash register ringing in your favor...beautiful, ain't it?
Lol! You and Starbuxsux are playing the heck out of these ATM (a.k.a Algo-ran) stocks. Good job!
Happy Holidays everyone. There isn't much left in 2014 in the market. I will see you all in 2015 on the green side of the wall.
Good luck and best wishes in 2015.
Happy Holidays everyone. There isn't much left in 2014 in the market. I will see you all in 2015 on the green side of the wall.
Good luck and best wishes in 2015.
$ANV = ATM
I'm going to be kicking myself in the arse going into 2015. I got stuck in a bio that I thought was going to move. Hopefully, it will in 2015.
Lesson learned. I believe $ANV is going to rocket once 2015 hits.
Algo trading machines are on $ANV hard now.
Where can I find this on Seeking Alpha? Link?
I never thought about that...some companies may already be aware of their award from BARDA. Very interesting.
The $100M shelf from IBIO and the lack of insider selling during the last run-up lets me know that big things are on the way.
I don't believe we will hear a peep from BARDA, IBIO or any of the other Ebola plays until the New Year.
The January Effect may reward you well. This end-of-year trading cycle taught me to hold some cash for spikes and setups like $ANV as well as Algo Trading which is the Santa Claus of the stock market...delivering gifts of shares at rock bottom prices.
Algos gonna give you opportunities for bargain prices. I think ANV is going to run hard beginning 2015. The January effect will hit it hard.
Until the New Year, watch the Algos do their thing and run this ticker down yet again.
2015.
BOOM!
Notice that price is dropping on very very little volume. Indicates the stock is being held tightly and not traded much. Also, recent run showed ZERO inside sells.
The insiders are telling you bigger days are ahead for this company. $3 a share is small potatoes and they know it. Listen to the insiders through their filings or lack thereof.
Plus the $100M shelf was registered in expectation of some ridiculously big stuff going on. You don't just pull a $100M shelf reg out for nothing. All bullish actions, in my opinion.
9 more trading days until 1/5/2015. Tax loss selling done, contract announcements coming, bogus lawsuits fall away. Even if the lawsuits hang around, I feel they will ultimately get dismissed.
I've been watching $ANV for a while. It is an ATM stock. $$$$$
Breaking News: Law firms suing IBIO found three lead plaintiffs.
You may want to sell your shares on Monday as these 3 plaintiffs were featured on the Colbert Report before coming forward.
LIVE: Pres Obama's Last News Conference of 2014:
http://www.whitehouse.gov/live/president-obama-holds-news-conference
LIVE: Pres Obama's Last News Conference of 2014:
http://www.whitehouse.gov/live/president-obama-holds-news-conference
LIVE: Pres Obama's Last News Conference of 2014:
http://www.whitehouse.gov/live/president-obama-holds-news-conference
What bears want you to believe about IBIO and other ebola stocks:
$IBIO: Bullish reset is coming 1/5/2015. All signs are pointing to it. The more DD I do, the more I am confident in this company.
Algos still fishing for volume as they are bouncing Level 2 all over the place. It appears support is starting to come up to where the Algos are.
Good stuff. Can't beat the computers...might as well watch 'em and learn.
Good points!
I have been digging up so much stuff on IBIO, it's ridiculous. This company has a lot of potential. While there are zero guarantees for success, I am liking their chances.
12/17/14: Top 10 Patent Losses of 2015
A second article is below this one
http://www.fiercepharma.com/special-reports/top-10-patent-expirations-2015
December 17, 2014 | By Tracy Staton
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are still reeling.
But in 2015, generics are expected to take a much smaller bite from the drugs losing exclusive access to their respective markets. That's because several of the big expiries involve biotech drugs. Even if biosimilar versions of these meds--Amgen's ($AMGN) Neulasta, for instance--do make it to market in the U.S. next year, their impact on sales is likely to be limited. According to EvaluatePharma, only $16 billion in sales will actually be lost to patent expiration next year. That's way less than half.
That's because biosimilar drugs may not be automatically substitutable for the brands they're seeking to replace. There's a battle going on over this exact issue: Biosimilar makers want their drugs to be labeled with the same generic names as the brands; branded drugmakers say biosims should carry their own unique names.
If the biosim makers win, their drugs will more easily substitute for brands, digging deeper into brand sales when patents expire. If the unique-name advocates prevail, doctors will have to prescribe biosimilars specifically, and brands will be better insulated.
"With forecasts now to 2020, we have an extended view of how equity analysts are modeling the impact of biological patent expiries and the subsequent entry of biosimilar products," Evaluate Pharma said in a recent report. "[T]hey continue to expect a softer landing, post-patent expiry, and limited biosimilar substitution.
"It seems future metaphorical patent cliffs are being transformed into much more manageable rolling hills."
And for some of these first few biologics going off patent, the substitution issue won't apply--because biosimilar meds aren't even waiting in the wings. AstraZeneca's ($AZN) Synagis, for instance, may lose patent protection next year, but a biosimilar from iBio is still in preclinical testing.
While next year's sales-at-risk number may be good news for biologics makers--and the pharma industry in general--it doesn't soften the blow for several companies in particular. Some of the blockbusters set for generic competition in 2015 are regular old small-molecule meds. Take Bristol-Myers Squibb ($BMY) and Otsuka's antipsychotic drug Abilify. It accounted for $2.3 billion of Bristol-Myers' sales in 2013, about 14% of its total for the year. For Otsuka, the impact is even larger, with Abilify making up a full quarter of its sales.
And then there's Lantus, the basal insulin treatment from Sanofi. It could be headed for a quick slide--just not immediately. It's not an easy-to-copy product, but Boehringer Ingelheim and Eli Lilly ($LLY) have already won approval for their biosimilar version in Europe, and the two companies are raring to go in the U.S.
But though Sanofi's U.S. patent on Lantus expires in February, the French drugmaker sued Lilly and Boehringer for patent infringement under the Hatch-Waxman Act. That lawsuit triggered an automatic 30-month stay on copycat launches, which stands to keep Lantus copies off the market till June 2016. Sanofi will be scrambling next year to build sales for some follow-up diabetes products, hoping to soften the blow when the lawsuit is resolved.
Meanwhile, there's Teva Pharmaceutical Industries ($TEVA) and its top-selling drug Copaxone. The multiple sclerosis treatment's exclusivity actually expired earlier this year, thanks to a court decision invalidating Teva's September 2015 patent. Would-be copycats like Mylan ($MYL) said they were poised to launch their versions. But Teva appealed to the Supreme Court, which agreed to hear its case. Teva also reminded the generics makers that if they launched and the high court ruled against them, Teva could collect two times their sales in damages. So far, no generic has yet launched. The reprieve will definitely end when the patent expires in September, however--if not sooner.
We should mention a couple of drugs that would have appeared on this list, had courts not intervened. Novartis ($NVS) won a patent fight over Gleevec, its blockbuster blood-cancer treatment, putting off potential biosimilars till 2016. On the other hand, GlaxoSmithKline ($GSK) lost a patent dispute involving its cardiovascular pill Lovaza, derived from fish oil; generics hit the market earlier in 2014.
In all, the 10 drugs on this list represent more than $32 billion in global sales. The patent expirations we cite affect only U.S. sales directly, however. Some of the drugs have already lost patent protection in Europe; others have more exclusivity to come. We gathered information on sales and patents from the companies' securities filings and annual reports; the FDA's Orange Book; patent expiration listings from pharmacy benefits managers Catamaran, Express Scripts and Community Catalyst; and EvaluatePharma. Fierce editors Stacy Lawrence, Carly Helfand and Emily Wasserman all contributed. Questions or comments? Let any of us know via email or Twitter. And if you're interested in previous versions of this list, check out the top 10 drug patent losses of 2014 and the top 15 of 2013. -- Tracy Staton (email | Twitter)
Article from 10/16/14:
http://www.fiercepharma.com/special-reports/top-10-patent-expirations-2015-synagis
Synagis
October 16, 2014 | By Carly Helfand
Synagis (palivizumab)
Company: AstraZeneca
Disease: Monoclonal antibody to prevent respiratory syncytial virus infection in infants
Global 2013 sales: $1.1 billion
Patent expiration date: October 2015
Synagis is already struggling ahead of a looming patent expiry, making it a not particularly tempting target for a biosimilar. Its sales were only $375 million during the first half of 2014, down 10% from the same period a year earlier.
In July, for the fifth time, the American Academy of Pediatrics (AAP) guidelines recommended less usage because the drug isn't particularly effective for any children other than the most premature infants. Respiratory syncytial virus (RSV) causes mild, coldlike symptoms; children are commonly infected by two years of age. But it is the leading cause of pneumonia in infants.
The drug was approved in 1998 for use in certain "high-risk" children, such as premature infants born at 35 weeks or earlier.
Only 20% of hospitalized infants are actually suitable for Synagis treatment, Dr. H. Cody Meissner, a member of an AAP committee involved in drafting the new guidance and a professor of pediatrics at Tufts University School of Medicine, told The Wall Street Journal for a July article.
The most recent AAP guidance calls for use of the drug in infants born before 29 weeks, older preemies with chronic lung disease or certain heart problems and certain other at-risk children younger than two years old. AstraZeneca ($AZN) estimated that previous restrictions eliminated about 100,000 infants from eligibility, while these new ones took out 40,000 more.
Synagis has been shown in studies to reduce the risk of hospitalization but not to reduce hospital stays or chances for long-term complications or death.
Despite the difficulties of the biosimilar pathway in the U.S., at least one company, iBio ($IBIO), has a preclinical palivizumab biosimilar. The micro-cap company says it has a deep pipeline of large-molecule drugs dependent on a biosimilar regulatory pathway. The costly Synagis is priced at about $1,000 for each of 5 required monthly injections.
I think $IBIO is forming a Chutes and Ladders pattern on the intrastate chart technically speaking.
One indicator to follow is HFI - Hustle and Flow Index. This measures the rate at which MMs are pimping the stock for gains.
Also, monitor the S & P 499 as well.
Get 'em, AMM!
Now we begin the march towards 2015 for contracts, vaccine and treatment trials and hopefully quite a few retail multi-thousandaire and millionaire investors and traders. Fingers crossed.
I saw that. Awwwwwesome!!!1 Although I am not in $TKMR right now, I try to post general ebola-related news here that may be of interest to investors and traders here.
Good luck.
12/16/14: Obama Signs $1.1 Trillion Spending Bill Into Law
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109132797
12/16/14: Obama Signs $1.1 Trillion Spending Bill Into Law
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109132797
12/16/14: Obama Signs $1.1 Trillion Spending Bill Into Law
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109132797
12/16/14: Obama Signs $1.1 Trillion Spending Bill Into Law
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109132797